(Q79796313)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308968%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

title

Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308968%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308968%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

Phylinda L S Chan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308968%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

John G Nutt

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308968%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

publication date

17 February 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308968%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

published in

Pharmaceutical Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308968%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308968%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308968%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

791-802

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308968%20AND%20SRC:MED&resulttype=core&format=json

Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models

25 December 2019

cites work

1 reference

12 December 2020

Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials

1 reference

12 December 2020

Toxic and protective effects of L-dopa on mesencephalic cell cultures

1 reference

12 December 2020

DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group

1 reference

12 December 2020

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

1 reference

12 December 2020

Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease

1 reference

12 December 2020

L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity?

1 reference

12 December 2020

Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

1 reference

12 December 2020

A size standard for pharmacokinetics.

1 reference

12 December 2020

Multi-center study of Parkinson mortality with early versus later dopa treatment

1 reference

12 December 2020

Drug treatment effects on disease progression.

1 reference

12 December 2020

Pharmacokinetics and effects of levodopa in advanced Parkinson's disease

1 reference

12 December 2020

Evolution of the response to levodopa during the first 4 years of therapy.

1 reference

12 December 2020

Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid.

1 reference

12 December 2020

Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease

1 reference

12 December 2020

Levodopa and the progression of Parkinson's disease

1 reference

12 December 2020

Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease?

1 reference

12 December 2020

Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease

1 reference

12 December 2020

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease

1 reference

12 December 2020

Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease

1 reference

12 December 2020

Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

1 reference

12 December 2020

Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.

1 reference

12 December 2020

A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100)

1 reference

12 December 2020

Is levodopa toxic to human substantia nigra?

1 reference

12 December 2020

1 reference

12 December 2020

Mortality associated with early and late levodopa therapy initiation in Parkinson's disease

1 reference

12 December 2020

10.1007/S11095-006-9202-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308968%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference